Ultragenyx Pharmaceutical Inc
For the period ended Mar 31, 2024. Filed May 3, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 3, 2024
RARE$15.43-0.9%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Item 5. Other Information
During the three months ended March 31, 2024, the following directors and Section 16 officers adopted a Rule 10b5-1 trading arrangement intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Name and Title | Date Adopted | Aggregate Number of Shares of Common Stock to be Sold (Subject to Certain Conditions) | Plan End Date |
|---|---|---|---|
| Emil KakkisEVP, Chief Executive Officer and Director | March 1, 2024 | Up to 85,000 shares | February 28, 2025 |
| Karah ParschauerEVP, Chief Legal Officer and Corporate Affairs | March 5, 2024 | Up to 41,717 shares, 31,911 of which are shares to be acquired upon the exercise of stock options | March 5, 2025 |
| Shehnaaz Suliman,Board Member | March 8, 2024 | Up to 25,000 shares, all of which are shares to be acquired upon the exercise of stock options | March 7, 2025 |
| Eric CrombezEVP, Chief Medical Officer | March 11, 2024 | Up to 61,247 shares, 37,266 of which are shares to be acquired upon the exercise of stock options | March 14, 2025 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.